Recommendation of the President – Rezurock (belumosudil)
On 12 December 2025, the President of the Agency for Health Technology Assessment and Tariff System issued recommendation No. 193/2025 on the validity of issuing approvals for the reimbursement of the medicinal product Rezurock (belumosudil) for the indication: treatment of adult patients and children aged 12 years and older with chronic graft-versus-host disease (chronic GVHD) after failure of at least two previous lines of systemic therapy